Overview
- The deal secures DBT 3757, an investigational targeted protein degrader designed to eliminate MLLT1 and MLLT3 drivers of acute leukemias.
- DBT 3757 remains in IND-enabling and preclinical work after showing promising anti-cancer activity in laboratory and animal models, including data discussed at ASH 2024.
- Amgen said Dark Blue will be integrated into its research organization to speed development and bolster its early oncology pipeline.
- The companies reported a total potential value of up to $840 million but did not disclose the upfront payment.
- Dark Blue originated from University of Oxford research and was backed by Oxford Science Enterprises, Bristol Myers Squibb and Evotec.